Arrowhead Pharmaceuticals reported a GAAP loss of $18.506 million for 6 months of fiscal year 2022, down 2.5 times from $47.55 million in the previous year. Revenue increased 2.3 times to $179.244 million from $54.113 million a year earlier.
Arrowhead Pharmaceuticals reported a GAAP loss of $18.506 million for 6 months of fiscal year 2022, down 2.5 times from $47.55 million in the previous year. Revenue increased 2.3 times to $179.244 million from $54.113 million a year earlier. 
ir.arrowheadpharma.com
English (US) 